- Home
- ESEA vs IMMP Comparison
ESEA vs IMMP Comparison
Compare ESEA & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESEA
- IMMP
- Stock Information
- Founded
- ESEA 2005
- IMMP 1987
- Country
- ESEA Greece
- IMMP Australia
- Employees
- ESEA N/A
- IMMP N/A
- Industry
- ESEA Marine Transportation
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- ESEA Consumer Discretionary
- IMMP Health Care
- Exchange
- ESEA Nasdaq
- IMMP Nasdaq
- Market Cap
- ESEA 293.8M
- IMMP 264.7M
- IPO Year
- ESEA 2006
- IMMP N/A
- Fundamental
- Price
- ESEA $42.77
- IMMP $2.05
- Analyst Decision
- ESEA Buy
- IMMP Buy
- Analyst Count
- ESEA 1
- IMMP 2
- Target Price
- ESEA $53.00
- IMMP $8.50
- AVG Volume (30 Days)
- ESEA 35.7K
- IMMP 106.2K
- Earning Date
- ESEA 11-20-2024
- IMMP 11-26-2024
- Dividend Yield
- ESEA 5.61%
- IMMP N/A
- EPS Growth
- ESEA 16.05
- IMMP N/A
- EPS
- ESEA 16.98
- IMMP N/A
- Revenue
- ESEA $205,168,137.00
- IMMP $2,563,302.00
- Revenue This Year
- ESEA $13.42
- IMMP N/A
- Revenue Next Year
- ESEA $4.22
- IMMP $10.84
- P/E Ratio
- ESEA $2.52
- IMMP N/A
- Revenue Growth
- ESEA 14.96
- IMMP 9.59
- 52 Week Low
- ESEA $26.20
- IMMP $1.58
- 52 Week High
- ESEA $50.92
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- ESEA 53.34
- IMMP 55.82
- Support Level
- ESEA $39.67
- IMMP $1.85
- Resistance Level
- ESEA $41.91
- IMMP $2.06
- Average True Range (ATR)
- ESEA 1.30
- IMMP 0.10
- MACD
- ESEA 0.21
- IMMP 0.03
- Stochastic Oscillator
- ESEA 93.09
- IMMP 70.89
About ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.